Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Risk of second tumors and T-cell lymphoma after CAR T-cell therapy
Background The risk of second tumors after chimeric antigen receptor (CAR) T-cell therapy,
especially the risk of T-cell neoplasms related to viral vector integration, is an emerging …
especially the risk of T-cell neoplasms related to viral vector integration, is an emerging …
Hodgkin lymphoma and liquid biopsy: a story to be told
J Velasco-Suelto, L Gálvez-Carvajal… - Journal of Experimental …, 2024 - Springer
Hodgkin lymphoma (HL) represents a neoplasm primarily affecting adolescents and young
adults, necessitating the development of precise diagnostic and monitoring tools …
adults, necessitating the development of precise diagnostic and monitoring tools …
Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects
Classic Hodgkin lymphoma (cHL) treatment paradigms are undergoing a shift with the
integration of immune checkpoint inhibitors (ICIs) into both first-line and relapsed/refractory …
integration of immune checkpoint inhibitors (ICIs) into both first-line and relapsed/refractory …
Genomic profiling of circulating tumor DNA for childhood cancers
The utility of circulating tumor DNA (ctDNA) analysis has not been well-established for
disease detection and monitoring of childhood cancers, especially leukemias. We …
disease detection and monitoring of childhood cancers, especially leukemias. We …
Circulating tumor DNA sequencing for biologic classification and individualized risk stratification in patients with Hodgkin lymphoma
JM Heger, L Mammadova, J Mattlener… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE Current clinical challenges in Hodgkin lymphoma (HL) include difficult-to-treat
relapsed/refractory disease and considerable long-term toxicities of treatment. Since clinical …
relapsed/refractory disease and considerable long-term toxicities of treatment. Since clinical …
Advances in Hodgkin lymphoma research
R Küppers - Trends in Molecular Medicine, 2024 - cell.com
Hodgkin lymphoma (HL) has been and still is the most enigmatic lymphoid malignancy in
humans. Since the first molecular analysis of isolated Hodgkin and Reed–Sternberg (HRS) …
humans. Since the first molecular analysis of isolated Hodgkin and Reed–Sternberg (HRS) …
Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
Abstract Purpose: Classic Hodgkin lymphoma (cHL) is a B-cell lymphoma that occurs
primarily in young adults and, less frequently, in elderly individuals. A hallmark of cHL is the …
primarily in young adults and, less frequently, in elderly individuals. A hallmark of cHL is the …
Evolving molecular subty** of breast cancer advances precision treatment
R Shan, LJ Dai, ZM Shao, YZ Jiang - Cancer Biology & Medicine, 2024 - cancerbiomed.org
Breast cancer is the second most prevalent cancer globally. In 2022, approximately 2.3
million newly diagnosed cases of female breast cancer occurred worldwide, and more than …
million newly diagnosed cases of female breast cancer occurred worldwide, and more than …
Pathogenic variants associated with epigenetic control and the NOTCH pathway are frequent in classic hodgkin lymphoma
A Santisteban-Espejo, I Bernal-Florindo… - International Journal of …, 2024 - mdpi.com
Classic Hodgkin lymphoma (cHL) constitutes a B-cell neoplasm derived from germinal
center lymphocytes. Despite high cure rates (80–90%) obtained with the current multiagent …
center lymphocytes. Despite high cure rates (80–90%) obtained with the current multiagent …
Molecular biomarkers in classic Hodgkin lymphoma
Classic Hodgkin lymphoma is a unique B-cell derived malignancy featuring rare malignant
Hodgkin and Reed Sternberg (HRS) cells that are embedded in a quantitively dominant …
Hodgkin and Reed Sternberg (HRS) cells that are embedded in a quantitively dominant …